secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0001193125-23-166540
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech hits 225-patient enrollment milestone in Phase 3 melanoma trial; expanded to 380
--------------------------------------------------------------------------------

- 225 patients randomized in Phase 3 trial of IO102-IO103 + pembrolizumab for advanced melanoma.
- Interim ORR analysis now triggered; positive data could enable BLA for accelerated approval in U.S.
- Trial enrollment increased to 380 patients to potentially accelerate primary PFS endpoint.
- Company expects full enrollment by year-end 2023; cash runway through Q3 2024.
- CEO notes potential first vaccine approval in 2025 if interim analysis is positive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523166540/0001193125-23-166540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523166540/d481906d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-166540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer